PDCD1 and non-small cell lung carcinoma: A secondary analysis of a phase I study assessing the anti‐PD‐1 agent pembrolizumab in patients with advanced non‐small‐cell lung cancer (NSCLC) then showed that patients who received radiotherapy before (median: 9 months) the anti‐PD1 treatment had increased progression‐free survival (PFS) and overall survival (OS) compared with patients who did not receive prior radiotherapy (Shaverdian et al., 2017).